Acadia Pharmaceuticals, Inc. announces FDA Approval of Daybue

Acadia Pharmaceuticals, Inc. announces FDA Approval of Daybue

The team at Acadia Pharmaceuticals Inc. announced FDA Approval on their drug Daybue, for the first approved treatment for Rett syndrome, a genetic brain disorder, making it the first approved drug for this condition.

Modality Solutions helped Acadia bring the drug to market by developing and executing the transport validation strategy for Daybue. You can read the full press release here.